Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
摘要:
Overexpression of prosurvival proteins such as Bcl-2 and Bcl-X-L has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of cancer. We recently described the discovery of 1 (ABT-737), which binds Bcl-2, Bcl-X-L, and Bcl-w with high affinity, shows robust antitumor activity in murine tumor xenograft models, but is not orally bioavailable. Herein, we report that targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC50). The resulting compound, 2 (ABT-263), is orally efficacious in an established xenograft model of human small cell lung cancer, inducing complete tumor regressions in all animals. Compound 2 is currently in multiple phase 1 clinical trials in patients with small cell lung cancer and hematological malignancies.
PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
申请人:Long Daniel D.
公开号:US20130287730A1
公开(公告)日:2013-10-31
The invention provides compounds of formula (I):
wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
[EN] ARYL AMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ARYLAMIDE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015006100A1
公开(公告)日:2015-01-15
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
The invention provides compounds of formulas (I) or (II):
wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain
作者:Richard A Hartz、Vijay T. Ahuja、Susheel J. Nara、C.M. Vijaya Kumar、Jeffrey M. Brown、Linda J. Bristow、Ramkumar Rajamani、Jodi K. Muckelbauer、Daniel Camac、Susan E. Kiefer、Lisa Hunihan、Michael Gulianello、Martin Lewis、Amy Easton、Jonathan S. Lippy、Neha Surti、Sreenivasulu N. Pattipati、Manoj Dokania、Saravanan Elavazhagan、Kumaran Dandapani、Brian D. Hamman、Jason Allen、Walter Kostich、Joanne J. Bronson、John E. Macor、Carolyn D. Dzierba
DOI:10.1021/acs.jmedchem.1c00472
日期:2021.8.12
Effective treatment of chronic pain, in particular neuropathicpain, without the side effects that often accompany currently available treatment options is an area of significant unmetmedicalneed. A phenotypic screen of mouse gene knockouts led to the discovery that adaptor protein 2-associated kinase 1 (AAK1) is a potential therapeutic target for neuropathicpain. The synthesis and optimization
A compound of formula (I) wherein A, p, R1, R3, R4, R5, and R8 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, nematode and mollusc pests and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.